Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B

Pietro Lampertico, Mauro Vigan, Floriana Facchetti, Federica Invernizzi, Adriana Aroldi, Giovanna Lunghi, Pier Giorgio Messa, Massimo Colombo

Research output: Contribution to journalArticlepeer-review

Abstract

Background. To assess the long-term effectiveness and safety of adefovir (ADV) plus lamivudine (LMV) in LMV-resistant (R) kidney transplants with chronic hepatitis B, 11 such patients were treated with add-on ADV.Methods. Serum alanine aminotransferase, renal function and serum hepatitis B virus (HBV) DNA levels were assessed every 3 months; ADV mutations were searched for by INNO-LiPA HBV DR v2 assay.Results. During 36 months (12-48), nine patients cleared serum HBV DNA with a 3-year cumulative virological response rate of 88%, without the emergence of ADV mutations. ADV dose was reduced in six patients (55%) showing a decline of creatinine clearance, in the absence of proximal tubulopathy.Conclusions. In LMV-R kidney graft recipients, long-term add-on therapy with ADV is efficacious and safe with timely adaptation of ADV dose.

Original languageEnglish
Pages (from-to)2037-2041
Number of pages5
JournalNephrology Dialysis Transplantation
Volume26
Issue number6
DOIs
Publication statusPublished - Jun 2011

Keywords

  • adefovir dipivoxil
  • hepatitis B virus
  • lamivudine-resistance
  • renal transplantation

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Fingerprint Dive into the research topics of 'Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B'. Together they form a unique fingerprint.

Cite this